Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Long-Term Investments (2018 - 2022)

Historic Long-Term Investments for Arcturus Therapeutics Holdings (ARCT) over the last 5 years, with Q1 2022 value amounting to $131000.0.

  • Arcturus Therapeutics Holdings' Long-Term Investments fell 8950.32% to $131000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $131000.0, marking a year-over-year decrease of 8950.32%. This contributed to the annual value of $515000.0 for FY2021, which is N/A changed from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Long-Term Investments of $131000.0 as of Q1 2022, which was down 8950.32% from $515000.0 recorded in Q4 2021.
  • Arcturus Therapeutics Holdings' Long-Term Investments' 5-year high stood at $1.2 million during Q1 2021, with a 5-year trough of $100000.0 in Q1 2020.
  • Moreover, its 5-year median value for Long-Term Investments was $303000.0 (2019), whereas its average is $493111.1.
  • In the last 5 years, Arcturus Therapeutics Holdings' Long-Term Investments surged by 114800.0% in 2021 and then crashed by 8950.32% in 2022.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Long-Term Investments stood at $288000.0 in 2018, then dropped by 8.68% to $263000.0 in 2019, then plummeted by 61.98% to $100000.0 in 2020, then surged by 415.0% to $515000.0 in 2021, then tumbled by 74.56% to $131000.0 in 2022.
  • Its Long-Term Investments stands at $131000.0 for Q1 2022, versus $515000.0 for Q4 2021 and $670000.0 for Q3 2021.